Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Falchi

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Blood|January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood|January 5, 2026
Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell LymphomaDanny Luan, Ori Ben Valid, Ofrat Beyar-Katz, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Blood|January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood|January 5, 2026
Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell LymphomaDanny Luan, Ori Ben Valid, Ofrat Beyar-Katz, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 8